Metabolic dysfunction−associated liver disease and diabetes: Matrix remodeling, fibrosis, and therapeutic implications
Annals of the New York Academy of Sciences · 2024
DOI: 10.1111/nyas.15184 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of the New York Academy of Sciences, 2024. Verfasst von Weiguo Fan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA. Hauptthemen laut MEDLINE: Fatty Liver, Liver Cirrhosis. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 134 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Metabolic dysfunction−associated liver disease (MASLD) and steatohepatitis (MASH) are becoming the most common causes of chronic liver disease in the United States and worldwide due to the obesity and diabetes epidemics. It is estimated that by 2030 close to 100 million people might be affected and patients with type 2 diabetes are especially at high risk. Twenty to 30% of patients with MASLD can progress to MASH, which is characterized by steatosis, necroinflammation, hepatocyte ballooning, and in advanced cases, fibrosis progressing to cirrhosis. Clinically, it is recognized that disease progression in diabetic patients is accelerated and the role of various genetic and epigenetic factors, as well as cell–matrix interactions in fibrosis and stromal remodeling, have recently been recognized. While there has been great progress in drug development and clinical trials for MASLD/MASH, the complexity of these pathways highlights the need to improve diagnosis/early detection and develop more successful antifibrotic therapies that not only prevent but reverse fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
- Palo Alto VA Medical Center, Palo Alto, California, USA.
ORCID-Profile: Weiguo Fan
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Fan, W., Bradford, T. M., & Török, N. J. (2024). Metabolic dysfunction−associated liver disease and diabetes: Matrix remodeling, fibrosis, and therapeutic implications. Annals of the New York Academy of Sciences. https://doi.org/10.1111/nyas.15184
Vancouver
Fan W, Bradford TM, Török NJ. Metabolic dysfunction−associated liver disease and diabetes: Matrix remodeling, fibrosis, and therapeutic implications. Annals of the New York Academy of Sciences. 2024. doi:10.1111/nyas.15184
BibTeX
@article{Fan2024,
author = {Fan, Weiguo and Bradford, Toby M and Török, Natalie J},
title = {Metabolic dysfunction−associated liver disease and diabetes: Matrix remodeling, fibrosis, and therapeutic implications},
journal = {Annals of the New York Academy of Sciences},
year = {2024},
doi = {10.1111/nyas.15184}
}
EUVIMED